FN2 Earnings Intelligence

The Clorox Company earnings overview

Latest The Clorox Company (CLX) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportThe Clorox Company reports Tuesday, Nov 3, 2026 · After market closeConsensus EPS $1.09 · consensus revenue $1.88B
CLX FY2026 Q4 · Calendar Q3 2026

The Clorox Company

The call supports a cautiously constructive operating thesis: share gains, product innovation, early GOJO accretion, and productivity initiatives provide support, but inflation, category execution, and integration risks temper the outlook.

EPS surprise+1.2%
Market move+6.5%
CLX FY2026 Q3 · Calendar Q2 2026

The Clorox Company

Clorox's Q3 FY26 results tell a story of an earnings beat that the market treated as a miss. Headline EPS of $1.64 exceeded the $1.55 consensus by 5.8%, and revenue of $1.67 billion was essentially in line. Yet shares fell approximately 10% on an abnormal basis — the disconnect centered on gross margin pressure from ERP implementation disruptions and elevated input costs, particularly oil-driven commodity inflation. The GOJO Industries acquisition, closed April 1, adds roughly 10% to quarterly revenue but brings near-term gross margin dilution of about 50 basis points and $30 million in incremental interest expense. Management maintained guidance and struck a confident tone, pointing to cleaning innovation (PURE, Scentiva), Glad share recovery, and cost-savings acceleration into FY27. However, the Fresh Step litter reinvention is advancing slower than anticipated, and the Food…

EPS surprise+5.8%
Market move-9.7%
CLX FY2026 Q1 · Calendar Q4 2025

The Clorox Company

Clorox's earnings support a conditional recovery thesis: operational improvements and an H2 innovation pipeline could help restore demand and margins, but the evidence remains dependent on market-share recovery, execution, and cost control.

EPS surprise+3.9%
Market move+1.2%
CLX FY2025 Q4 · Calendar Q3 2025

The Clorox Company

The supplied analysis supports a conditional recovery case: Clorox’s brand strength, innovation pipeline, pricing discipline, and ERP-enabled productivity could support longer-term improvement, but near-term evidence is mixed because organic sales declined and execution, tariffs, and promotion remain material risks.

EPS surprise+30.5%
Market move-2.0%

Get the CLX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.